Response to therapy by disease stage in 146 study cases
| Stage . | No. . | No. (%) . | Median, mo (% at 2 y) . | ||||
|---|---|---|---|---|---|---|---|
| CHR . | CHRs . | MCyR . | CCyR . | OS . | EFS . | ||
| AP | 83 | 57 (69) | 45 (54) | 31 (37) | 23 (28) | 32 (61) | 9 (23) |
| BP | 57 | 13 (23) | 10 (17) | 21 (39) | 14 (26) | 9 (19) | 4 (7) |
| Ph+ ALL | 6 | 2 (33) | 2 (33) | 3 (50) | 2 (33) | 13 (33) | 2 (0) |
| Stage . | No. . | No. (%) . | Median, mo (% at 2 y) . | ||||
|---|---|---|---|---|---|---|---|
| CHR . | CHRs . | MCyR . | CCyR . | OS . | EFS . | ||
| AP | 83 | 57 (69) | 45 (54) | 31 (37) | 23 (28) | 32 (61) | 9 (23) |
| BP | 57 | 13 (23) | 10 (17) | 21 (39) | 14 (26) | 9 (19) | 4 (7) |
| Ph+ ALL | 6 | 2 (33) | 2 (33) | 3 (50) | 2 (33) | 13 (33) | 2 (0) |
CHRs indicates sustained CHR (ie, at least 4 weeks).